Efficacy and potential mechanisms of Chinese herbal compounds in coronavirus disease 2019: advances of laboratory and clinical studies

Mu-Feng Xiang†, Cheng-Tao Jin†, Li-Hua Sun2, Zhi-Hui Zhang3, Jing-Jing Yao4* and Liu-Cheng Li1*

Abstract
The Coronavirus disease 2019 (COVID-19) pandemic is still spread and has made a severe public health threat around the world. To improve disease progression, emerging Chinese herbal compounds were used in clinical practice and some agents have proven beneficial in treating COVID-19. Here, the relevant literature from basic researches to clinical application were identified and comprehensively assessed. A variety of Chinese herbal compounds have been reported to be effective in improving symptoms and outcomes in patients with COVID-19, particularly together with routine treatment strategy. The pharmacological activities were mainly attributed to the relief of clinical symptoms, inhibition of cytokine storm, and improvement of organ function. Besides, the development of novel antiviral drugs from medicinal herbs were further discussed. The updated laboratory and clinical studies provided the evidence of Chinese herbal compounds such as Lianhua Qingwen prescription, Shufeng Jiedu prescription, and Qingfei Paidu Tang for the relief of COVID-19. However, both of the randomized controlled trials and real world researches need to be done for supporting the evidence including the efficacy and safety in fighting COVID-19.

Keywords: Coronavirus, COVID-19, SARS-CoV-2, Chinese herbal compounds

Introduction
Respiratory disease is one of leading cause of death across the globe and bring great challenges to human health [1–3]. Coronavirus disease 2019 (COVID-19), infected with Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (SARS-CoV-2), has led to more than 250 million infections and 5 million deaths till now [4]. The World Health Organization (WHO) announced that COVID-19 became a global pandemic in March 2020.

COVID-19 was characterized by varied clinical symptoms including fever, cough, and fatigue, among whom the severe cases would result in acute respiratory distress syndrome (ARDS), as well as multiple organ failure, even death [5–7]. It remains grim to contain the spread and explore its effective treatment strategies. Since the early outbreak of COVID-19, China took timely measures to limit its spread, and officially issued several versions of the Guideline on Diagnosis and Treatment of Coronavirus Disease 2019. Traditional Chinese medicine (TCM) was recommended for the clinical use in China [5]. TCM have been used for thousands of years to prevent and cure various diseases, and have been a part of the integrative medicine field for developing novel drugs...
Fighting against SARS-CoV-2 infection provides an opportunity to test the true value of TCM in treating emerging contagious diseases. It is encouraging that recent data had proved that the oral preparations of Chinese herbal compounds were important agents for treating COVID-19 with symptom relief, virus inhibition, and immune function improvement, especially combined with conventional treatment regimens likely western immune function improvement, especially combined with conventional treatment regimens likely western medicine. This review will focus on providing an insight into the advances of current experimental and clinical experience of Chinese herbal compounds in treating COVID-19 (Table 1), to offer timely data delivery in human medicine.

### Treatment strategies from Chinese herbal compounds

In the severe SARS-CoV-2 outbreak, there is a concerted global effort to develop new drugs to combat this major plague. The studies showed that COVID-19 would cause multi-organ damage, and brought enormous challenge to the treatment of COVID-19. Recently, emerging herbal compounds have been demonstrated helpful to improve COVID-19 by exerting antiviral activities, inhibiting cytokine storm, regulating immune functions, and so forth. The relevant research advances, especially the emerging clinical studies

### Table 1 The herbal sources of Chinese herbal compounds

| Agents                     | Herbal sources                                                                 | References |
|----------------------------|--------------------------------------------------------------------------------|------------|
| Lianhua Qingwen prescription | Forsythia suspensa (Thunb) Vahl. (Lianqiao), Lonicera japonica Thunb. (Jinyinhu), Ephedra sinica Stapf (Mahuang), Arnebiae Amarum Semen (Kuxingren), Gypsum Fibrosum (Shigao), Isatis tinctoria L. (Banlangen), Dryopteris crassirhizoma Nakai (Mianmaguangzhong), Houttuynia cordata Thunb. (Yuxingcao), Pogostemon cablin (Blanco) Benth. (Guanghuoxiang), Rheum palmatum L. (Dahuang), Rhodolia rosea Linn. (Hongtingtian), Mentha haplocalyx Briq. (Bohe), Glycyrrhiza uralensis Fisch. (Gancao) | [5, 12, 17] |
| Shufeng Jiedu prescription  | Reynoutria japonica Houtt. (Huzhang), Forsythia suspensa (Thunb) Vahl. (Lianqiao), Isatis tinctoria L. (Banlangen), Bupleurum chinensis DC. (Chaihu), Patrinia villosa Juss. (Bajiangcang), Verbena officinalis Linn. (Mabiancao), Phragmites communis Trin. (Lugen), Glycyrrhiza uralensis Fisch. (Gancao) | [24, 28–30] |
| Huoxiang Zhengqi formulation | Atractylodes Lancea (Thunb) DC. (Cangzhú), Pericarpium Citri Reticulatae (Chenpi), Magnolia officinalis Rehd. et Wils. (Houpu), Angelica dahurica Fisch. ex Hoffm. Benth. et Hook.f. (Baizhi), Poria cocos (Schw.) Wolf. (Fuling), Areca catechu L. (Dafupi), Pinellia ternata (Thunb) Breit. (Baxia), Glycyrrhiza uralensis Fisch. (Gancao), Pogostemon cablin (Blanco) Benth. (Guanghuoxiang), Perilla frutescens (L.) Britt.var. crispa (Thunb) Hand.‑Mazz. (Zisuye) | [35, 36] |
| Qingfei Paifu Tang          | Ephedra sinica Stapf (Mahuang), Glycyrrhiza uralensis Fisch. (Gancao), Arnebiae Amarum Semen (Kuxingren), Gypsum Fibrosus (Shigao), Pinellia ternata (Thunb) Breit. (Banxia), Astra tataricae Linn.: f. (Ziwan), Tussilago farfara Linn. (Kuanzhong), Belamcanda chinensis (Linn.) Redouté (Shegan), Asarum sieboldii Miq. (Xin), Pericarpium Citri Reticulatae (Chenpi), Citrus aurantium L. (Zhishi), Zingiber officinale Rosc. (Shengjiang), Bupleurum chinensis DC. (Chaihu), Scutellaria baicalensis Georgi (Huangqin), Cinnamomum cassia Presl (Guizhi), Poria cocos (Schw.) Wolf. (Fuling), Alisma plantago-aquatica Linn. (Zexie), Polyporus umbellar L. (Pers) Fr. (Zhuling), Atractylodes macrocephala Koidz. (Baizhi), Dioscorea opposita Thunb. (Shanyao), Asarum sieboldii Franch. (Fisch. et Mey.) O. Ktze. (Huoxiang) | [41–43] |
| ShuangHuangLian oral liquid | Lonicera japonica Thunb. (Jinyinhu), Scutellaria baicalensis Georgi (Huangqin), Forsythia suspensa (Thunb) Vahl. (Lianqiao) | [51] |
| Jinhua Qinggan granule      | Lonicera japonica Thunb. (Jinyinhu), Gypsum Fibrosus (Shigao), Ephedra sinica Stapf (Mahuang), Arnebiae Amarum Semen (Kuxingren), Scutellaria baicalensis Georgi (Huangqin), Forsythia suspensa (Thunb) Vahl. (Lianqiao), Fritillaria thunbergii Miq. (Zhebeimu), Amaranthae asphodeloides Bunge (Zhimu), Arctium lappa L. (Niubangzi), Artemisia carvifolia Buch.-Ham. ex Roxb. (Qinghao), Mentha haplocalyx Briq. (Bohe), Glycyrrhiza uralensis Fisch. (Gancao) | [55, 56] |
| ReYanNing mixture           | Taraxacum mongolicum Hand.‑Mazz. (Pungongying), Reynoutria japonica Houtt. (Huzhang), Sanchus brachyotus DC. (Beibaijiang), Scutellaria barbata D. Don (Banzhilian) | [57] |
| Huopu Xialing decoction     | Agastache rugosa (Fisch. et Mey.) O. Ktze. (Huoxiang), Magnolia officinalis Rehd. et Wils. (Houpu), Pinellia ternata (Thunb) Breit. (Banxia), Semen Coicis Coix lachryma-jobi L.var.ma-yuen (Roman) stapf (Yiyiren), Arnebiae Amarum Semen (Kuxingren), Poria cocos (Schw) Wolf. (Fuling), Amomum kravanh Pierre ex Gagnep. (Baidoukou), Polyporus umbellar L. (Pers) Fr. (Zhuling), Alisma plantago-aquatica Linn. (Zexie), Tetrapanacis Medulla (Tongcao), Glycine max (L.) Merr. (Dandouchi) | [66] |
| XiaoChaiHu decoction         | Bupleurum chinensis DC. (Chaihu), Pinellia ternata (Thunb) Breit. (Banxia), Panax ginseng C. A. Mey. (Renshen), Glycyrrhiza uralensis Fisch. (Gancao), Scutellaria baicalensis Georgi (Huangqin), Zingiber officinale Rosc. (Shengjiang), Ziziphus jujuba Mil1. Var.inermis (Bge.) Rehd. (Dazao) | [69] |
| MaXingShiGan decoction      | Ephedra sinica Stapf (Mahuang), Arnebiae Amarum Semen (Kuxingren), Glycyrrhiza uralensis Fisch. (Gancao), Gypsum Fibrosus (Shigao) | [77] |
| Yupingfeng prescription     | Astragalus membranaceus (Fisch.) Bunge. (Huangqi), Atractylodes macrocephala Koidz. (Baizhi), Saposhnikovia divaricata (Trucz.) Schischk. (Fangfeng) | [69] |
Table 2: The clinical/biological effects of Chinese herbal compounds for COVID-19 patients

| Agents                      | Clinical/biological effects                                      | Type of clinical study                                      | References |
|-----------------------------|------------------------------------------------------------------|-------------------------------------------------------------|------------|
| Lianhua Qingwen prescription| Improved symptoms including fever, cough, muscle pain, fatigue and chest tightness | Single-center retrospective study                           | [12]       |
| Shufeng Jiedu prescription  | Time of defervescence ↓, disappear time of symptoms (dry cough, stuffy nose, runny nose, sore throat, fatigue, and diarrhea) ↓, time of SARS-CoV-2 turning negative ↓, clinical effectiveness ↑ | Single-center retrospective study                           | [28]       |
|                            | Improvement in pneumonia associated symptoms                     | Case report                                                 | [29]       |
|                            | Time of defervescence ↓, white blood cell count ↑, lymphocyte percentage ↑, CRP ↓, IL-6 level ↓ | Retrospective cohort study                                  | [30]       |
| Huoxiang Zhengqi formulation| Incidence of colds ↓, incidence of adverse events and adverse reactions ↓ | Large cohort, prospective, randomized, and parallel-controlled study | [35]       |
|                            | Improved symptoms (nausea, vomiting and limb soreness), utilization rate of anti-infective drugs ↓, proportion of cases progressed to severe disease ↓ | Randomized controlled study                                 | [36]       |
| Qingfei Paidu Tang          | Risk of in-hospital mortality ↓ | National retrospective registry study                      | [41]       |
|                            | Improved creatine kinase, creatine kinase-myocardial band, lactate dehydrogenase, and blood urea nitrogen levels, CRP ↓ | Single-center retrospective study                           | [42]       |
|                            | Median length of hospital stay and nucleic acid negative conversion ↓, sputum disappearance time ↓, chest CT absorption rate ↑ | Multi-center retrospective study                           | [43]       |
| ShuangHuangLian oral liquid | Nucleic acid negative conversion rate ↑, inflammatory focus absorption ↑ | Randomized, open-label, parallel-controlled, multi-center trial | [51]       |
| Jinhua Qinggan granule      | Duration of nucleic acid negative conversion ↓, pneumonia recovery time ↓ | Single-center retrospective study                           | [55]       |
|                            | Disappearance rate of clinical symptoms (fever, cough, fatigue, expectoration) ↑, anxiety score ↓ | Prospective randomized controlled trial                    | [56]       |
| ReYanNing mixture           | Symptom scores (dry throat, cough, fatigue, chest tightness and headache) ↓, nucleic acid negative conversion rate ↑, median time to complete fever clearance ↓ | Multi-center retrospective study                           | [57]       |
| Huopu Xialing decoction     | Improved liver function, viral nucleic acid and chest CT         | Case report                                                 | [66]       |
| XiaochaiHu decoction        | Disappearance rate of cough, sputum, shortness of breath, poor appetite and chills ↑, improvement rate of lung CT manifestations ↑ | Single-center retrospective study                           | [69]       |
| MaXingShiGan decoction      | Effective rate ↑, antipyretic time ↓, cough disappearance time ↓ | Prospective randomized controlled trial                    | [77]       |
| Yupingfeng prescription     | Shortened course of fever, cough and sputum, ameliorated symptoms such as fever, cough, sputum, painful pharynx, improved CRP and lung CT manifestations | Single-center retrospective study                           | [69]       |

CRP C-reactive protein, CT computerized tomography, IL interleukin, SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2

(Table 2), will provide comprehensive insights into the containment of the viral epidemic.

**Lianhua Qingwen prescription**

Lianhua Qingwen is a commonly used Chinese medical preparation to treat viral influenza, especially in the fight against SARS in 2002–2003 in China [5, 11]. Wang et al. showed that 7 days after treatment with Lianhua Qingwen prescription (6 g, three times a day) in conjunction with conventional treatment for COVID-19 had a total effective rate of 92.73% accompanied by significantly reduced major symptoms including fever, cough, fatigue, and chest tightness [12]. The network pharmacology analysis confirmed that its effects was mainly focused on the biological processes such as the response to lipopolysaccharide (LPS), the molecular response to bacterial origin, the response to metal ions, and cell biological stimulation [12]. It may benefit the treatment of COVID-19 by the signaling pathways such as tumor necrosis factor (TNF), sarcoma-associated herpesvirus infection, interleukin (IL)-17, and human cytomegalovirus infection [12]. Other studies also showed that the effects of...
Lianhua Qingwen prescription was related to virus infection, inflammation, and immunity, moreover, its main active ingredients were verified by molecular docking with angiotensin-converting enzyme 2 (ACE2), the functional receptor of SARS-CoV-2, so as to have a therapeutic effect on COVID-19 [13, 14].

Lianhua Qingwen prescription also significantly inhibited SARS-CoV-2 replication in Vero E6 cells, markedly reduced the production of pro-inflammatory cytokines such as TNF-α, IL-6, chemokine (C-C motif) ligand 2 (CCL-2)/monocyte chemoattractant protein-1 (MCP-1), and chemokine (C-X-C motif) ligand 10 (CXCL-10)/interferon-inducible protein-10 (IP-10), and resulted in abnormal particle morphology of virion in cells [15]. Recent analysis indicated that Lianhua Qingwen prescription could act by regulating immune response, apoptosis, and virus infection [16]. Its active compounds beta-carotene, kaempferol, luteolin, naringenin, quercetin, and wogonin, could target RAC-alpha serine/threonine-protein kinase (Akt1), which is involved in lung injury, lung fibrogenesis, and virus infection, thereby helping eliminate virus infection with COVID-19 [16]. A meta-analysis involving 3793 subjects indicated that there was significant improvement of fever, fatigue, cough, and muscle pain in the Lianhua Qingwen group compared to the conventional drug group for treating common pneumonia and COVID-19 pneumonia [17].

Though emerging data showed its benefits on viral infection including SARS-CoV-2, the incidence of gastrointestinal reactions (diarrhea, abdominal distension, and gastrointestinal discomfort) was high as reported [18]. On April 14, 2020, the National Medical Products Administration (NMPA) of China approved modifying the specification of Lianhua Qingwen by adding a new indication for COVID-19 treatment [5]. However, its efficacy and safety should be confirmed by more clinical practices.

**Shufeng Jiedu prescription**

Shufeng Jiedu prescription is composed of eight herbs [19]. An antibacterial testing suggested that Shufeng Jiedu prescription was a broad-spectrum antibacterial that superior to Lianhua Qingwen capsules with lowered mortality rate, increased average survival time, and increased lifespan of mice dying due to a Staphylococcus aureus or Streptococcus infection [20]. It also had a broad spectrum of antiviral effect and has a good therapeutic effect on pneumonia caused by parainfluenza virus [21, 22].

Shufeng Jiedu prescription also played a significant role in regulating immune function by significantly reducing the levels of IL-1α, IL-1β, IL-2, IL-4, IL-10, TNF-α, interferon (IFN)-α, and IFN-γ in a rat model of streptococcus pneumoniae-induced pneumonia [23]. Network pharmacology analysis revealed that it reduced the activity of nuclear factor kappa-B (NF-κB) via several signaling pathways, while its active ingredients quercetin, wogonin, and polydatin could bind directly to the main protease (Mpro) of SARS-CoV-2 [24]. Another study showed that Shufeng Jiedu prescription may prevent COVID-19 through its active ingredients likely quercetin, luteolin, wogonin, and kaempferol by targeting TNF, IL-10, IL-2, IL-6, STAT1, and CCL-2 [25]. It was also demonstrated that Shufeng Jiedu prescription may exert immunomodulatory and anti-inflammatory effects to control the current coronavirus, while RELA, MAPK1, MAPK14, CASP3, CASP8 were also the key target genes [26, 27].

Shufeng Jiedu prescription (2.08 g, three times per day) has been recently reported effective in the improvement of pneumonia associated symptoms when treating the patients of COVID-19, in combination with western medicine including lopinavir/ritonavir (Kaletra) and/or arbidol [28, 29]. Shufeng Jiedu prescription in combination with Arbidol and traditional Chinese and western allopathic medicine to treat common-type COVID-19, could improve its recovery time, and had better clinical effectiveness with higher white blood cell count and lymphocyte percentage, but lower C-reaction protein (CRP) and IL-6 levels [30]. It was also showed that Shufeng Jiedu prescription added to standard antiviral therapy, significantly reduced fatigue as well as cough days of COVID-19 compared to standard antiviral therapy alone, which was significantly more effective when used within the first 8 days after the onset of symptoms [24]. These evidence strongly suggested that Shufeng Jiedu prescription could be used as a complementary treatment to improve the efficacy of COVID-19 patients.

**Huoxiang Zhengqi formulation**

Huoxiang Zhengqi formulation is a Chinese medical formula that mainly composed of ten kinds of herbs [19]. Modern pharmacological studies have found that Huoxiang Zhengqi formulation has antiviral, anti-inflammatory, and immunomodulatory activities [31, 32]. A systematic review has evaluated the efficacy and safety of Huoxiang Zhengqi formulation in treating gastrointestinal type symptoms [33]. The results showed that the efficacy of Huoxiang Zhengqi formulas is better than that of western medicine (formulations Paracetamol and Amantadine Hydrochloride or ribavirin) [33]. It was also better than conventional treatment alone (rehydration and antiviral therapy) when combining with conventional treatment [33]. Besides, it is more effective in improving the clinical symptoms (chills, fever, and bowel diarrhea) than western medicine treatment. Early application of Chaishu Droplet pill (1.05 g, twice daily) and Huoxiang Zhengqi
formulation (5 g, twice daily) in treating SARS could alleviate the injury in lung of SARS patients and the neutrophil dependent inflammatory reaction, and reduce the dosage of glucocorticoid used [34].

Yan and colleagues showed that the preventive administration of Huoxiang Zhengqi Oral Liquid (oral before meals, 10 mL/time, 2 times/day, a course of 5 days) could effectively protect against respiratory symptoms, such as colds, on community residents in the case of COVID-19 [35]. Recent randomized controlled clinical trial indicated that Huoxiang Zhengqi dropping pills and Lianhua Qingwen formulation combined with western medicine had significant advantages in reducing the utilization rate of anti-infective drugs and improving the prognosis for COVID-19 patients [36]. Huoxiang Zhengqi formulation has been recommended in the treatment of COVID-19 by the National Health Commission (NHC) of China [37]. Further well-designed trials with large sample size are warranted to clarify its regulatory mechanisms and medication safety.

**Qingfei Paidu Tang**

Qingfei Paidu Tang (or named Qingfei Detox Soup or Qingfei Paidu Decoction) is a mixture of twenty-one herbal components [38, 39]. Fan et al. showed that Qingfei Paidu Tang could be used to relieve internal and external pressure, and regulate triple energizer by promoting lung Qi, dispelling evil and detoxification, moistening and dampening, and purging heat by removing water, which is suitable for the pathogenesis of COVID-19 including cold, dryness, and dampness, and should effectively improve clinical symptoms [38]. Xu et al. reported that quercetin, luteolin, kaempferol, naringin, and isorhamnetin were the main active components of Qingfei Paidu Tang in the treatment of COVID-19 [40]. These agents could inhibit inflammatory reaction, regulate immune function, reduce lung injury and protect nerve function by regulating targets to achieve the purpose of treating COVID-19, such as mitogen-activated protein kinase 1 (MAPK1), MAPK3, MAPK8, MAPK14, IL-6, RELA proto-oncogene (RELA), and signal transducer and activator of transcription 1 (STAT1) [40].

Qingfei Paidu Tang treatment was associated with a lower risk of in-hospital mortality than those not receiving it, without extra risk of acute liver injury or kidney injury among hospitalized COVID-19 patients [41]. In mild and moderate COVID-19 patients, the combination of Qingfei Paidu Tang with western medicine demonstrated improved CRP, creatine kinase, creatine kinase-myocardial band, lactate dehydrogenase, and blood urea nitrogen levels, tended to mitigate the extent of multi-organ impairment, but neither mortality nor length of hospitalization was affected [42]. However, recent report showed that the single use of Qingfei Paidu Tang was more effective than the combination regimen with western medicine or other proprietary Chinese medicine [43]. It demonstrated that Qingfei Paidu Tang could significantly promote the improvement of nucleic acid negative conversion, chest CT, and sputum symptoms, and shortening the length of hospital stay than the combination therapy in light/common type of COVID-19 patients from five hospitals [43]. Another retrospective multicenter cohort study including 782 confirmed COVID-19 patients indicated that Qingfei Paidu Tang was associated with improved outcomes including faster recovery, shorter time to viral shedding, and less duration of hospital stay [44]. Further multicenter, prospective trials should be conducted to further confirm its clinical value.

**ShuangHuangLian oral liquid**

ShuangHuangLian is a Chinese traditional patent medicine composing of three herbs [45]. ShuangHuangLian oral liquid combined with oseltamivir showed much higher effective rate and immunoglobulin A (IgA), IgM, and IgG levels than that of oseltamivir after the treatment of pediatric influenza [46]. Meanwhile, the remission time of patients with fever, cough, and general malaise was obviously shorter with ShuangHuangLian oral liquid treatment [46]. In vitro, either ShuangHuangLian oral liquid, the lyophilized powder of ShuangHuangLian for injection or their bioactive components dose-dependently inhibited 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 and SARS-CoV-2 replication in Vero E6 cells [47]. In addition, two ingredients of ShuangHuangLian, baicalin, and baicalein, were the noncovalent, non-peptidomimetic inhibitors of SARS-CoV-2 3CLpro and exhibited potent antiviral activities in a cell-based system [47].

Network pharmacology analysis showed that ShuangHuangLian oral liquid (the active formulations included quercetin, beta-sitosterol, neo baicalein) shared 28 targets with COVID-19, such as caspase-3, tumor protein p53 (TP53), MAPK8, IL-6, CCL-2, and the main pathways related to hepatitis b, TNF signaling pathway, pulmonary tuberculosis, whooping cough, salmonella infection, swine flu, as well as herpes simplex virus infection pathway [45]. Further evidence indicated that the chemical components of ShuangHuangLian had a good binding ability with 3CLMPro, ACE2, and the complex [48]. Besides, ShuangHuangLian exerted the effects of antivirus, anti-inflammatory, inhibition of oxidative stress and cell apoptosis, and may also be related to inhibit virus infection of host cells and interfere with virus replication and proliferation [48, 49]. In clinical, Ni et al. then reported three cases from a family case of COVID-19 treated with the combination of western medicine and
ShuangHuangLian oral liquid (20 mL, twice daily), suggesting the expected therapeutic effects of ShuangHuangLian oral liquid on COVID-19 [50]. Patients with 14-day ShuangHuangLian oral liquid treatment had significantly higher rate in negative conversion of SARS-CoV-2 in nucleic acid swab tests with more absorption of inflammatory focus of pneumonia than the standard therapy alone [51]. It provides the theoretical basis and scientific basis for the treatment of COVID-19 with ShuangHuangLian oral liquid.

Jinhua Qinggan granule

Jinhua Qinggan granule (JHG) composes of twelve herbs [52]. In a study of treating influenza of wind-heat affecting Fei syndrome, Li et al. divided the patients into the high dose JHG group (10 g each time), the low dose JHG group (5 g JHG + 5 g placebo each time), and the placebo control group (10 g placebo each time), and all medication was administered three times daily for 5 days [52]. The result demonstrated that the markedly effective rate of TCM symptoms and the recovery rate in the low dose JHG group was significantly higher than that of other groups both after 3 days and 5 days after treatment, respectively [52]. Then similar effects and safety were obtained in the low dose JHG group and the high dose JHG group, but the effects of the high dose JHG group was slightly poor in partial indicators, revealing the routinely low dose was the optimal dosage of JHG [52].

The “herbal medicine-compound-target” study elucidated that JHG was involved in TNF, phosphoinositide 3-kinase (PI3K)/Akt and hypoxia inducible factor (HIF)-1 signaling pathways which were related to lung injury protection, meanwhile, formononetin, stigmasterol, beta-sitosterol, anhydroicaritin and other key compounds of JHG have a certain degree of affinity with SARS-CoV-2 3CL hydrolase and ACE2 [53]. Recent network pharmacology study indicated that the biological processes involved in the key gene targets of JHG were cytokine activity, MAPK activity, chemokine activity, inflammatory response, immune response, while the signaling pathways in the treatment of COVID-19 included TNF, influenza A, HIF-1, NOD receptor, toll-like receptor (TLR), vascular endothelial growth factor (VEGF), MAPK, and T cell receptor signaling pathways [54].

In COVID-19 patients, JHG could effectively shorten the duration of nucleic acid detection and increase the absorption of pneumonia inflammatory exudate [55]. Compared with conventional treatment, the combination with JHG (6 g, three times daily for 5 days) significantly reduced the clinical symptoms of fever, cough, fatigue, expectoration, and relieved the anxiety of patients with mild COVID-19, but the incidence of adverse reactions in JHG group was significantly higher [56]. These data support that JHG should act as an effective agent in treating COVID-19, but its regulatory mechanism, effects, and safety are needed to be clarified with large sample data in the real world.

ReYanNing Mixture

ReYanNing Mixture has good effects in the treatment of upper respiratory tract infection, cold, fever, acute pharyngitis, pneumonia, and many other respiratory diseases [57]. In a HCoV-229E infected mouse model, ReYanNing Mixture markedly reduced the lung index of coronavirus pneumonia mice, increased the percentage of CD8$^+$ T lymphocytes, CD4$^+$ T lymphocytes, total B lymphocytes, and reduced virus load as well as the levels of IFN-γ, TNF-α, IL-6, and IL-10 [58]. The in vivo study suggested obvious effects of ReYanNing Mixture in improving lung lesions, enhancing the autoimmune function, and reducing the inflammatory factors release, which provided laboratory evidence for its potential clinical benefits [58].

In addition, ReYanNing Mixture was reported to produce marked anti-inflammatory effects by regulating CD40LG, CXCL10, CXCL8, IL-10, IL-2, and IL-6, which was involved in IL-17 signaling pathway and cytokine-cytokine receptor interaction pathway by network topology analysis [59]. The molecular docking results revealed that its active compounds including apigenin, chrysin, and catechin, were identified with higher docking score rank against SARS-CoV-2 3CL protease, most of them were attributed to flavonoids [59]. Furthermore, the candidate targets including TNF, IFN-γ, TP53, CRP, and peroxisome proliferator-activated receptor γ (PPARY), were identified among the bioactive ingredients of ReYanNing Mixture with effects on treating SARS-CoV-2 [60].

Recent study showed that the symptom scores such as dry throat, cough, fatigue, chest tightness and headache in COVID-19 patients was significant reduced with the treatment using ReYanNing Mixture (10–20 mL, 2–4 times per day) on the basis of chemical drug treatment compared with the chemical drug treatment only [57]. Besides, the median time to complete fever clearance with ReYanNing Mixture treatment was shorter, and the negative conversion rate of viral nucleic acid detection was higher [57]. These data revealed that ReYanNing Mixture may benefit COVID-19 by both anti-inflammatory and anti-virus actions, but the clinical evidence were far from sufficient.

Huopu Xialing Decoction

Huopu Xialing Decoction consists of eleven herbs [61]. A few years ago, a small sample clinical trial had showed that Huopu Xialing Decoction has good clinical efficacy in treating Pi-Wei dampness-heat syndrome [62]. Recent study has also confirmed that the application of
Huopu Xialing Decoction in the treatment of COVID-19 patients in Wuhan of China showed obvious clinical efficacy, and 697 targets were screened from TCM Systems Pharmacology Database, and 43 targets of which were related to COVID-19 and mainly involved in the IL-17 and NF-κB signal pathways [61].

A network pharmacology study showed that quercetin, luteolin, and baicalein were the main compounds of Huopu Xialing Decoction, which might regulate multiple signaling pathways targeting Akt1, MAPK1, cyclin D1 (CCND1), and caspase-8, thus played a therapeutic role on COVID-19 [63]. Meanwhile, other similar researches further demonstrated that the active components of Huopu Xialing Decoction had anti-inflammatory, immune regulation, anti-pulmonary fibrosis effects, and might protect against COVID-19 by regulating the biological processes such as blocking the protein synthesis of SARS-CoV-2 virus, preventing the virus from entering the host cells, and regulating TNF, MAPK, TLR, NOD-like receptor, and HIF-1 signaling pathways [64, 65]. Recent study showed that Huopu Xialing Decoction had obvious effects on improving symptoms, liver function, viral nucleic acid and chest CT in the treatment of COVID-19 patients with liver injury caused by other antiviral drugs [66]. Further clinical evidence in COVID-19 is still needed.

**XiaoChaiHu Decoction**

XiaoChaiHu Decoction is a TCM compound preparation consisting of seven kinds of herbs [67]. Modern studies have shown that XiaoChaiHu Decoction can induce the activities of natural killer (NK) cells and T cells in liver tissues, and induce immune factors such as IL-1β, IL-2, and IFN-γ, so as to enhance the ability of virus clearance [19, 68]. A network pharmacology study showed that 140 active ingredients in XiaoChaiHu Decoction was for pneumonia treatment and immune regulation through 95 key targets such as IL-6, inducible nitric oxide synthase (NOS2), and estrogen receptor 1 (ESR1), involving TNF and IL-17 signaling pathways, and influenza A, of which 12 ingredients had direct anti-SARS-CoV-2 activity including baicalein, formononetin, quercetin [67]. The analysis result also indicated that the active ingredients in XiaoChaiHu Decoction treated COVID-19 by inhibiting SARS-CoV-2 activity, blocking SARS-CoV-2 invasion, inhibiting cytokine storm, and regulating immunity, but may not be effective for diseases such as alveolar inflammation.

A small sample clinical study proved that XiaoChaiHu Decoction and YuPingFeng prescription in combination with conventional therapy significantly shortened the course of fever, cough, and sputum in suspected cases of COVID-19, when compare to conventional therapy alone [69]. Besides, the combination treatment regimen also ameliorated the symptoms such as fever, cough, sputum, painful pharynx, shortness of breath, chills, and improved the CRP as well as lung computed tomography (CT) manifestations in patients [69]. Collectively, XiaoChaiHu Decoction may play a beneficial role in COVID-19 treatment, but need further randomized controlled studies to understand its exact clinical efficacy and safety.

**MaXingShiGan Decoction**

MaXingShiGan Decoction consists of four kinds of herbs [70]. MaXingShiGan Decoction, the solution of heat and lung antiasthmatic prescription, is often used to treat respiratory diseases such as upper respiratory tract infection, acute bronchitis, acute attack of chronic bronchitis, and bronchial asthma in clinical [19]. Hsieh and partners observed that MaXingShiGan Decoction exhibited an EC(50) of 0.83±0.41 mg/mL against influenza virus A/WSN/33 (H1N1), with broad-spectrum inhibitory activity against different strains of human influenza A viruses, including clinical oseltamivir-resistant isolates and an H1N1pdm strain [71]. Besides, MaXingShiGan Decoction abolished viral entry that regulated by PI3K/Akt signaling pathway. Zhong and collages showed that MaXingShiGan Decoction could improve H1N1 influenza A virus-induced acute lung injury (ALI) in mice, accompanied by decreased lung cell apoptosis and reduced the serum content of TNF-α [72]. In a rat model of lipopolysaccharides (LPS)-induced pneumonia, the thrombin and TLR signaling pathway were demonstrated to be essential pathways for MaXingShiGan Decoction mediated anti-inflammatory effects, while glycyrrhizic acid (one major compound in MXSG) inhibited TLR agonists induced IL-6 production in macrophage [73].

The network analysis of MaXingShiGan Decoction in severe COVID-19 predicted its main active components (quercetin, kaempferol, wogonin, naringenin, and isorhamnetin) with key targets including CCL-2, IL-1β, IL-4, IL-6, IL-10, MAPK1, MAPK3, MAPK8, TNF, caspase-3, Akt1, TP53, VEGFA, epidermal growth factor (EGF), and EGF receptor (EGFR) [74, 75]. A variety of its active ingredients could act on inflammatory responses (inflammatory cells, inflammatory cytokines, and their signaling pathways), immune responses, virus defense, humoral immunity, and mucosal innate immune response, and thus played a therapeutic role on COVID-19 [1, 75].

Treating infantile pneumonia with MaXingShiGan Decoction was reported superior to improve the disappearance time of lung moist rales, wheeze, cough, and fever than that without MaXingShiGan Decoction treatment [76]. Recent study demonstrated that modified MaXingShiGan Decoction combined with Sanren Decoction combined with conventional treatment
(antiviral, immunomodulator, intestinal flora regulator, symptomatic treatment) had higher effective rate, and shorter time of antipyretic and cough disappearance [77]. The data revealed the potential effects of MaXingShiGan Decoction in COVID-19 therapy.

**YuPingFeng prescription**

YuPingFeng prescription is a classical complex prescription composed of three herbs in a dry weight ratio of 3:1:1 [8]. Total glycoside and polysaccharides of YuPingFeng, the mixed extracts from *Yupingfeng*, were demonstrated to have immunoregulatory, anti-inflammatory, and anti-fibrotic activities [78–80]. Recent clinical study showed that YuPingFeng granules (5 g, three times per day) had a significantly lower exacerbation rate and reduced second exacerbation risk than the placebo treatment with a good safety profile during the prevention of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) [81]. The meta-analyses also reported that YuPingFeng was effective to treat asthma in children, meanwhile, YuPingFeng combined with routine western medicine therapy for recurrent respiratory tract infection could improve the total effective rate and immune function with no serious adverse reaction [82, 83].

Huang et al. had recently proved that the core active compounds in YuPingFeng prescription could regulate multiple signal pathways by binding with ACE2 to ESR1, prostaglandin-endoperoxide synthase 2 (PTGS2) and other targets based on network pharmacology and molecular docking technology [84]. YuPingFeng prescription and XiaoChaiHu Decoction combined with routine treatment could improve the outcomes of suspected COVID-19 patients than routine treatment alone [69]. However, it was just a small sample of suspected cases with COVID-19. The benefits of YuPingFeng prescription as well as its extracts in COVID-19 deserve further in-depth studies and clinical attempts.

**Concluding remarks and future perspectives**

The global public health crisis infected by SARS-CoV-2 has resulted in a fatality rate of 2% among infected patients [4]. To wipe out such plague epidemic, increasing efforts have turned to exploring the effective treatment regimens. However, the development of novel drugs is a systematic project, which is often a long and arduous process. The discovery of new actions with old drugs on the market becomes the principal way to explore the treatment of COVID-19. The fight against such epidemic provides a chance to test the role of TCM in the treatment of emerging infectious diseases. As a unique medical practice, Chinese herbal compounds have exerted its advantages in the treatment of COVID-19 [4, 24, 42]. The official report showed that 91.5% of confirmed COVID-19 cases received TCM (including oral Chinese herbal compounds) in China while the total effective rate was more than 90%, indicating the satisfactory therapeutic superiority with TCM in the treatment of COVID-19 [85]. Up to now, NHC has released the latest versions of Guidelines for Diagnosis and Treatment of COVID-19 [86]. Several Chinese herbal compounds that illustrated in this review, such as Huoxiang Zhengqi formulation, Lianhua Qingwen prescription, Shufeng Jiedu prescription, Jinhu Qinggan granule, and Qingfei Paidu Tang have been recommended for the treatment of COVID-19 by NHC on account of the disease stage and symptom differentiation [86].

The present study showed that the clinical effects of Chinese herbal compounds for COVID-19 treatment mainly included improved symptoms (fever, cough, muscle pain, fatigue) and lung CT manifestations, decreased risk of in-hospital mortality and adverse reactions, and increased inflammatory focus absorption as well as nucleic acid negative conversion rate. The updated evidence also demonstrated that the pharmacological mechanisms of Chinese herbal compounds for COVID-19 were mainly attributed to the down-regulated virus activity, inhibited cytokine storm, and enhanced immune function (Fig. 1). 3CLpro is critical for the replication and activity of virus, and thus may represent a promising therapeutic target for SARS-CoV-2 [87]. Here, the reports showed that following Chinese herbal compounds had the capacity to suppress the enzymatic activity of SARS-CoV-2 3CLpro: ShuangHuangLian oral liquid, Jinhu Qinggan granule, and ReYanNing Mixture [47, 48, 53, 59]. Interestingly, *Lonicera japonica* Thunb. (Jinyinhua), *Scutellaria baicalensis* Georgi (Huangqin), and *Forsythia suspensa* (Thunb.) Vahl. (Lianqiao) were the same herbal components of ShuangHuangLian oral liquid and Jinhu Qinggan granule. It was elucidated that the cellulessence of SARS-CoV-2 was host receptor ACE2, and thus blockade of ACE2 holds the promise to prevent SARS-CoV-2 infection. In this study, we found that Lianhua Qingwen prescription, ShuangHuangLian oral liquid, Jinhu Qinggan granule, and YuPingFeng prescription may protect against SARS-CoV-2 infection by targeting ACE2 [13, 14, 48, 53, 84]. Similarly, the former three compounds contain herbal components of *Lonicera japonica* Thunb. (Jinyinhua) and *Forsythia suspensa* (Thunb.) Vahl. (Lianqiao). In-depth exploration of their active components on SARS-CoV-2 3CLpro and ACE2 may be beneficial for screening anti-COVID-19 agents.

In some patients, SARS-CoV2 infections will not turn into severe COVID-19 [88]. However, the systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection will result in cytokine storm and severe outcomes in COVID-19 [7, 88]. Therefore,
anti-inflammatory agents presumably could decrease the severity and mortality rate of COVID-19 patients. Among the listed Chinese herbal compounds reviewed here, Shufeng Jiedu prescription, Qingfei Paidu Tang, ShuangHuangLian oral liquid, Jinhua Qinggan granule, Huopu Xialing Decoction, and MaXingShiGan Decoction were demonstrated to regulate MAPK signaling pathway \[27, 40, 45, 54, 64, 74\]. Meanwhile, ReYanNing Mixture, Huopu Xialing Decoction, and XiaoChaiHu Decoction had the activity to inhibit both IL-17 and TNF signaling pathways \[59, 61, 67\]. The inflammatory mediators like IL-6 and NF-κB were the other two major targets for most of the Chinese herbal compounds proposed in this study \[25, 45, 61\]. Chinese herbal compounds with the capacity to inhibit pro-inflammatory cytokine release may be harnessed to restrain multiple organ dysfunction and disease progression in the treatment of COVID-19.

However, there are potential study limitations that need to be addressed. First of all, the demonstrated efficacy of Chinese herbal compounds for COVID-19 were mostly from in vitro and in vivo studies, small-scale clinical trials, or the medication experience from the traditional use to COVID-19 therapy, and thus lack sufficient supporting evidence to some extent. Though the recent studies exerted therapeutic potential of Chinese herbal compounds for COVID-19, most of the clinical studies were retrospective studies or found to be poorly designed. It may lead to biases in evaluating the effects of Chinese herbal compounds. Therefore, further large-scale randomized controlled trials are still needed.

Secondly, growing studies speculated the potential mechanisms and benefits of Chinese herbal compounds for COVID-19 via network pharmacology-based analysis. It aims to reduce the time and cost of preclinical drug screening, and lead to more precise drugs and lower drug attrition rates. In fact, whether they protect against SARS-CoV-2 needs continuous experimental investigations as well as the feedback from serious clinical practice. In addition, the active molecules repeatedly found in different Chinese herbal compounds may not indicate a genuine result, but rather nonspecific interactions by specific molecules. Evaluating the importance of different targets will greatly facilitate the development of COVID-19 therapy.

Thirdly, Chinese herbal compounds in combination with western medicine had been reported effective to significantly improve the clinical symptoms and living quality during COVID-19 therapy. Nevertheless, the studies lacked the classification of disease severity and control group with Chinese herbal compounds treatment. Meanwhile, the clinical trials on the role of Chinese herbal compounds in COVID-19 mainly come from China, and none of these agents were approved by other countries till now. As searched in ClinicalTrials.gov (https://www.clinicaltrials.gov/), there are several ongoing clinical trials outside of China. Singapore designed a randomized controlled trial assessing the efficacy of Lianhua...
Qingwen as an adjuvant treatment in patients with mild symptoms of COVID-19 (ClinicalTrials.gov identifier: NCT04433013), but the recruitment status is “Not yet recruiting” up to now. Another study was to evaluate the effectiveness and safety of Jinhua Qinggan granules on mild-category patients of COVID-19 in Pakistani population (ClinicalTrials.gov identifier: NCT04723524), while the estimated study completion date was August 2021. We look forward to the evidence provided by these studies. Certainly, further well-designed multicenter trials from different countries are needed before an exact conclusion can be drawn. To work together against COVID-19, the exchange of experience in drug therapy should be strengthened, including the preferred use of Chinese herbal compounds that have been proven to be effective in multiple trials.

Fourthly, the dosages of Chinese herbal compounds for COVID-19 were based on previous published clinical data in other diseases. Besides, some of them are produced by different manufacturers, their quality standards may have differences. In order to obtain as accurate data as possible, the quality standards for drug production need to be harmonized. It is also necessary to investigate the effects of different doses of Chinese herbal compounds on different degrees of disease.

The last but not least, Chinese herbal compounds use may also bring adverse drug reactions, but the evidence is insufficient. Some Chinese herbal medicines contain renal toxins and mutagens, but their toxicological characteristics are still unclear. In addition, herbs used in TCM can mimic, amplify or counter the effects of traditional medicines. The complex components stand for multiple targets and pleiotropic effects, which may also bring more adverse drug reactions. Hence, the researches on the safety of Chinese herbal compounds should be carefully evaluated, especially from the real world data. In addition, it is of particular importance to avoid toxicity or interfere with the efficacy of routine treatment caused by herb-drug interaction. For example, it was not suitable to take both Lianhua Qingwen prescription and tonic herbs for COVID-19 cases at the same time. Due to the ethanol component contained in Huoxiang Zhengqi formula, metronidazole, furazolidone, cefoperazone and sulbactam, and ceftriaxone as well as other drugs that could cause disulfiram-like reaction must be avoided in combination. It was also noteworthy that plenty of other TCM prescriptions that were crucial to the prevention and management of complicated diseases but not investigated yet, may shed light on more alternative natural compounds with the capacity to fight against COVID-19. In addition, standardized products of Chinese herbal compounds, rather than self-prepared formulations with no accepted standard of quality control, should be encouraged in the future study. The last but not least, it is recommended that clinical pharmacists can closely participate in COVID-19 treatment, such as prescription review and rational use of Chinese herbal compounds, to ensure the safety of drug use.

In conclusion, this study summarized the comprehensive and updated evidence of Chinese herbal compounds such as Lianhua Qingwen prescription, Shufeng Jiedu prescription, and Qingfei Paidu Tang for COVID-19 treatment. However, most of these studies were in vitro experiments or poorly designed retrospective trials, which may lead to potential biases in assessing the efficacy of Chinese herbal compounds in COVID-19. It is expected to further carry out randomized controlled trials in line with international standards and large-sample studies in the real world, to support the efficacy and safety of Chinese herbal compounds in the fight of COVID-19.

Abbreviations
3Cpro: 3-Chymotrypsin-like protease; ACE2: Angiotensin-converting enzyme 2; Akt1: RAC-alpha serine/threonine-protein kinase; ALI: Acute lung injury; ARDS: Acute respiratory distress syndrome; CCL-2: Chemokine (C-C motif) ligand 2; CCND1: Cyclin D1; COVID-19: 2019 Coronavirus disease; CRP: C-reactive protein; CT: Computed tomography; CXCL-10: Chemokine (C-X-C motif) ligand 10; EGF: Epidermal growth factor; ESR1: Estrogen receptor 1; HGF: Growth differentiation factor; IFN: Interferon; IgA: Immunoglobulin A; IL: Interleukin; IP-10: Interferon-inducible protein-10; MAPK: Mitogen-activated protein kinase; MCP-1: Monocyte chemotractant protein-1; NF-κB: Nuclear factor kappa-B; NHC: National Health Commission; NK: Natural killer; NMPA: National Medical Products Administration; NOS2: Inducible nitric oxide synthase; PPARγ: Peroxisome proliferator-activated receptor γ; PTGS2: Prostaglandin-endoperoxide synthase 2; RELA: RELA proto-oncogene; SARS: Severe Acute Respiratory Syndrome; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; STAT1: Signal transducer and activator of transcription 1; TCM: Traditional Chinese medicine; TLR: Toll-like receptor; TNF: Tumor necrosis factor; TP53: Tumor protein p53; VEGF: Vascular endothelial growth factor; WHO: World Health Organization.

Acknowledgements
We would like to thank Dr. Jiao Qu (State Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Science, Nanjing University, China) for the help as a consultant.

Authors’ contributions
MFX and CTJ contributed equally to this work. LCL and MFX designed the review. LCL and ZHZ collected the literatures. LCL and JJY were responsible for drafting the manuscript. CTJ and MFX revised the manuscript. ZHZ, LHS and LCL analyzed the literatures and made the tables. All authors approved the final version of this manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (Nos. 81503129, 82104486), the Zhejiang Provincial Science Technology Projects of Traditional Chinese Medicine (No. 2021ZB174), the Zhejiang Provincial Natural Science Foundation of China (No. LLY19H280006), the Shanghai Hongkou District Family Planning Commission Project (No. Hongwei1903-03), the Budget Research Project of Shanghai University of Traditional Chinese Medicine (No. 2020LK082), the Natural Science Research Project Funding of Higher Education Institutions of Anhui Province (No. KJ2020A0332), State-level College Students’ Innovative Entrepreneurial Training Plan Program (Nos. 202110361117, S202110361235), and University-level Key Projects.
and Start-up Funds of Anhui University of Science and Technology (Nos. QN2019104, 13190308).

Availability of data and materials
The datasets are included within the article.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare no conflict of interest.

Author details
1 Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China. 2 Department of Diagnostic Ultrasound & Echocardiography, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China. 3 Institute of Vascular Disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China. 4 Key Laboratory of Industrial Dust Prevention and Control & Occupational Health and Safety, Ministry of Education, Anhui University of Science and Technology, Huainan 232001, China.

Received: 13 November 2021   Accepted: 19 November 2021

Published online: 03 December 2021

References
1. Li SY, Li JC, Ma EX, Gu J, Shi ZL. Analysis of potential drug effective substance and mechanism of Ma-Xing-Shi-Gan decoction in treating COVID-19. J Southwest Minzu Univ (Nat Sci Ed). 2020;46:354–69.
2. Luo H, et al. Reflections on treatment of COVID-19 with traditional Chinese medicine. Chin Med. 2020;15:94.
3. Li LC, Han YY, Zhang ZH, Zhou WC, Fang HM, Qu J, Kan LD. Chronic obstructive pulmonary disease treatment and pharmacist-led medication management. Drug Des Dev Ther. 2021;15:111–24.
4. World Health Organization. Coronavirus disease (COVID-19) pandemic. Geneva: WHO. 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 12 Nov 2021.
5. Li LC, et al. Lianhua Qingwen prescription for coronavirus disease 2019 (COVID-19) treatment: advances and prospects. Biomed Pharmacother. 2020;130:102754.
6. Soy M, Keser G, Ataogunduz P, Tabak F, Ataogunduz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39:2085–94.
7. Yang CX, Qu J, Liu YT, Meng SW, Wang BL, Feng MQ, Sun Y. Immune imbalance mechanism and intervention strategy in patients with coronavirus disease 2019 (COVID-19). Chin Pharmacol Bull. 2020;36:445–53.
8. Liang Z, Chen X, Shi J, Hu H, Xue Y, Ung COL. Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: a systematic literature review of randomized controlled trials. Chin Med. 2021;16(1):9.
9. Ng JY. The regulation of complementary and alternative medicine professions in Ontario, Canada. Integr Med Res. 2020;9(2):12–6.
10. Han L, et al. Potential mechanism prediction of Cold-Damp Plague Formula against COVID-19 via network pharmacology analysis and molecular docking. Chin Med. 2020;15:78.
11. Zhuang J, Dai X, Wu Q, Cai H, Fu X, Zhang W, Chen B. A meta-analysis for Lianhua Qingwen on the treatment of coronavirus disease 2019 (COVID-19). Complement Ther Med. 2021;60:102754.
12. Wang FC, Shen BX, He CY, Zhao WC, Nie SL. Clinical efficacy and mechanism of Lianhua Qingwen granule on COVID-19 based on network pharmacology research. Pharmacol Clin Chin Mater Med. 2020;36:93–101.
13. Ling XY, Tao JL, Sun X, Yuan B. Exploring material basis and mechanism of Lianhua Qingwen prescription against coronavirus based on network pharmacology. Chin Trad Herb Drug. 2020;51:1723–30.
14. Wang L, Yang ZH, Zhang HR, Yu HY, Yang K, Fu BH, Yang HT. Study on the network pharmacology and evidences of Lianhua Qingwen in the treatment of novel coronavirus (2019 nCoV) Pneumonia. J Chin Med Mater. 2020;43:772–8.
15. Runfeng L, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156:104761.
16. Xia QD, et al. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19. Cell Prolif. 2020;53:e12949.
17. Hu C, Liang M, Gong F, He B, Zhao D, Zhang G. Efficacy of Lianhua Qingwen compared with conventional drugs in the treatment of common pneumonia and COVID-19 pneumonia: a meta-analysis. Evid Based Complement Alternat Med. 2020;2020:5157089.
18. Wang SH, Liu JF, Zhang YL, Dong Z. Systematic review of efficacy and safety of Lianhua Qingwen capsules in treatment of viral influenza. Zhongguo Zhong Yao Za Zhi. 2019;44:1503–8.
19. Song JX, Zhang ZH, Zhao SM, Li H, Guo J. Patent information analysis on traditional Chinese medicine for prevention and treatment of COVID-19. Drug Evs Res. 2020;43:565–90.
20. Bao Y, Gao Y, Cui X. Effect of Shufeng jiedu capsules as a broad-spectrum antibacterial. Biosci Trends. 2016;10:74–8.
21. Bao YY, Gao YJ, Shi YJ, Bao L, Yao RM, Mao X, Cui XL. Study on broad-spectrum antiviral effect of Shufeng Jiedu capsules. J New Chin Med. 2019;51:5–8.
22. Ji S, Bai Q, Wu X, Zhang DW, Wang S, Shen JL, Fei GH. Unique synergistic antiviral effects of Shufeng Jiedu capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease. Biomed Pharmacother. 2020;121:109652.
23. Ma L, Huang Y, Hou YB, Bi HY, Pan J, Ge DZ, Liu J, Zhang TJ. Compatibility rationality and mechanism of Shufeng jiedu capsule in treatment of pneumonia. Drug Evs Res. 2019;42:1769–73.
24. Xia L, et al. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19: antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. Phytomedicine. 2021;85:153390.
25. Xiong H, Dong Z, Lou G, Gan Q, Wang J, Huang Q. Analysis of the mechanisms of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools. Eur J Integr Med. 2020;40:101241.
26. Chen X, Yin YH, Zhang MY, Liu YJ, Li R, Qu YQ. Investigating the mechanism of Shufeng JieDu capsule for the treatment of novel coronavirus pneumonia (COVID-19) based on network pharmacology: Int J Med Sci. 2020;17:2511–30.
27. Tao Z, Zhang L, Friedemann T, Yang G, Li J, Wen Y, Wang J, Shen A. Systematic analyses on the potential immune and anti-inflammatory mechanisms of Shufeng Jiedu capsule against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused pneumonia. J Funct Foods. 2020;75:104243.
28. Qu XK, et al. A retrospective study on the treatment of COVID-19 by Shufeng Jiedu capsule combined with abidor. Chin Trad Herb Drug. 2020;51:1167–70.
29. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and western medicine treatment. Biosci Trends. 2020;14:64–8.
30. Chen J, Lin S, Niu C, Xiao Q. Clinical evaluation of Shufeng Jiedu capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study. Expert Rev Respir Med. 2021;15:257–65.
31. Hua ZR, Liu XX, Hao L, Wang Y, He Y, Zhou SP, Yan KJ. Research progress on potential application of Huoxiang Zhengqi for prevention and treatment of coronavirus disease 2019. Drug Clin. 2020;35:1–6.
32. Yu DD, Liao X, Xie YM, Li HM, Zhang YL, Wang GQ, Zhao J. Systematic review and meta-analysis of Huoxiang Zhengqi pills combined with western medicine for acute gastroenteritis. Zhongguo Zhong Yao Za Zhi. 2019;44:2914–25.
33. Zhao HU, et al. Huoxiang Zhengqi formulas for treatment of gastrointestinal type cold: a systematic review and meta-analysis. Zhongguo Zhong Yao Za Zhi. 2017;42:1495–9.
34. Li H, Lu CZ, Tang KC. Clinical observation on treatment of SARS with combination of chaihu droplet pill and huoxiang zhengqi droplet pill. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004;24(2):321–4.
35. Yan BH, et al. Large-scale prospective clinical study on prophylactic intervention of COVID-19 in community population using huoxiang zhengqi oral liquid and JinHua Jiee granules. Zhongguo Zhong Yao Za Zhi. 2020;45:2993–3000.
36. Xiao M, et al. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: a randomized controlled trial. Pharmaco Res. 2020;161. 105126.
37. Lu Y, et al. Literature analysis of Chinese patent medicine treatment in the observation period of clinical management of coronavirus disease 2019 (trial 6th edition). Clin Med. J. 2020;18:62–6.
38. Fan YP, Wang YP, Ma Y, Zhao C, Zhang HM. Analysis on composition mechanism of Qingfei Paidu Tang from pathogenesis of cold pestilence of COVID-19. Chin J Exp Trad Med Form. 2020;43:26–32.
39. Peng RQ, Yang SJ, Xie CG, Shen QL, Li MQ, Wei X, Li JK, Huang M. Clinical observation of Qingfeipaidu decoction in the treatment of COVID-19. Pharm Clin Chin Mater Med. 2020;36:13–8.
40. Xu DY, Xu YL, Wang ZW, Lu YL, Song T. Mechanism of Qingfei-paidu decoction on COVID-19 based on network pharmacology. Pharm Clin Chin Mater Med. 2020;36:13–8.
41. Zheng L, et al. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: a national retrospective registry study. Phytomedicine. 2021;85:153531.
42. Xin S, et al. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment. Biomed Pharmacother. 2020;129:110500.
43. Sun BN, et al. A multi-center clinical study of Qingfei Paidu Tang on 295 cases of mild/common type COVID-19. J Trad Chin Med. 2021;62:599–603.
44. Shi N, et al. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. Pharmaco Res. 2020;161:105290.
45. Zheng ZW, He WQ, Liu CF. Study on mechanism of Shuanghuanglian oral liquid in treating novel coronavirus pneumonia based on network pharmacology. J Chin Med Mater. 2020;43:2074–80.
46. Gao YL, Wang LL. Effect of children Shuanghuanglian mixture combined with oseltamivir phosphate in the treatment of influenza. J Clin Pathol Res. 2020;40:332–6.
47. Su HK, et al. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin. 2020;41:1167–77.
48. Xie LH, Lin XY, He P, Liu Y, Hu GH. Research on Shuanghuanglian oral liquid for treatment of COVID-19 based on network pharmacology and molecular docking technology. J Huaian Univ Chin Med. 2020;40:1123–31.
49. Yang ZH, Yan HF, Yan YF, Wang L, Ji YS, Wang SP. Study on the molecular mechanism of Shuanghuanglan oral liquid inhibiting novel coronavirus (2019-nCoV) based on network pharmacology. J Chin Med Mater. 2020;43:2333–40.
50. Ni L, Zhou L, Zhou M, Zhao J, Wang DW. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan. Front Med. 2020;14:210–4.
51. Ni L, et al. Effects of Shuanghuanglan oral liquids on patients with COVID-19. A randomized, open-label, parallel-controlled, multicenter clinical trial. Front Med. 2021;5:1–14.
52. Li GQ, et al. Treating influenza patients of wind-heat affecting Fei syndrome by Jinhu Qinggan granule: a double-blinded randomized control trial. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013;33:1631–5.
53. Gong PY, Guo YJ, Li XP, Wang N, Gu J. Exploring active compounds of Jinhu Qinggan granules for prevention of COVID-19 based on network pharmacology and molecular docking. Chin Trad Herb Drug. 2020;51:1685–93.
54. Lin JR, Zheng WW, Zeng GX, Lin QZ. Study on the network pharmacology of Jinhu Qinggan granules in the treatment of COVID-19. J Chin Med Mater. 2020;43:2074–80.
55. Liu Z, et al. Effect of Jinhu Qinggan granules on novel coronavirus pneumonia in patients. J Tradit Chin Med. 2020;40:467–72.
56. Duan C, et al. Clinical observation on Jinhu Qinggan granule combined with conventional western medicine therapy in treating mild cases of coronavirus disease 2019. J Trad Chin Med. 2020;61:1473–7.
57. Yang MB, Dang SS, Huang S, Li Y, Guo YL. Multi-center clinical observation of Reyanning mixture in treatment of novel coronavirus pneumonia. Chin J Exp Trad Med Form. 2020;26:7–12.
58. Bao L, Shi Y, Geng ZH, Sun J, Zhao RH, Du CQ, Chu YJ, Cui XL. Application of network mixture in evaluating combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome. Zhongguo Zhong Yao Za Zhi. 2020;45:1465–72.
59. Wang M, et al. Mechanism prediction and anti-virus compounds selection of Reyanning mixture in the treatment of COVID-19 based on network pharmacology and molecular docking technology. Mod Chin Med. 2020;52:248–91.
60. Yang AP, Liu H, Liu F, Fan LX, Liao WQ, Gu JL, He K. Study of the mechanism of the Reyanning mixture involved in treating novel coronavirus pneumonia based on network pharmacology. Nat Prod Commun. 2020;15:1–12.
61. Xie YZ, & SL, Zhong CT, Zhan SF, Huang HT, Liu XH. Study on the mechanism of Huopuxiaoling decoction in treating coronavirus disease base on network pharmacology. J Chin Med Mater. 2020;43:1284–94.
62. Zhuo DT, Lu JY, Huang LP. Effect of modified huopo xialing decoction in treating p¯-wei dampness-heat syndrome and its impact on the tongue epithelial cell apoptosis. Zhongguo Zhong Yi Yi He Za Zhi. 2011;3:168–71.
63. Zhao HH, et al. Study on the potential mechanism of HuoPu Xialing decoction in the treatment of COVID-19 based on network pharmacology. Pharmaco Clin Chin Mater Med. 2020;36:79–85.
64. Fan MY, Liu J, Sun R. Analysis on material basis and efficacy network of HuoPu Xialing decoction in treating damp pathogen stagnation of lung syndrome of early COVID-19. Chin Trad Herb Drug. 2020;51:2297–306.
65. Fu C, Zhao Y, Xie M, Xiao HH, Li HM, Yang ZJ, Zuo XH. Study on the mechanism of HuoPu Xialing decoction based on network pharmacology to explore the treatment of COVID-19. J Basic Chin Med. 2020;26:640–4.
66. Yang PY, Yang MB, Qin LZ, Fu QQ. Experience of HuoPu Xialing decoction in the treatment of antiviral drug induced liver injury in COVID-19 patients. J Shanxi Univ Chin Med. 2021;44:9–17.
67. Sun KB, Zhang XY, Liu J, Sun R. Network pharmacological analysis and mechanism prediction of Xiahoutai decoction in treatment of COVID-19 with syndrome of pathogenic heat lingering in lung and obstructive cardinale. Chin Trad Herb Drug. 2020;51:1750–60.
68. Chen C, Liu YH, Cheng SB, Wu SL, Zhai XJ. The hepatoprotective effects of XHD and Mglg against methotrexate-induced liver injury and inflammation in rats through suppressing the activation of ALM2 inflammatory-cytokines. Pathol Res Pract. 2020;216:152675.
69. Zheng JL, Lu BJ. Clinical observation of Xiaoauhui decoction combined with Yupingfeng powder in the treatment of suspected cases of COVID-19. J Liaoning Univ Chin Trad Med. 2020;23:134–7.
70. He ZY, Wu KY, Liang GY, Jin FY, Li X, Feng H. Effect of different composition in Maxingxiang decoction on contents of glycyrrhizic acid. Chin Pharm J. 2008;43:264–7.
71. Hsieh CF, Lo CW, Liu CH, Lin S, Yen HR, Lin TY, Hong JF. Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. J Ethnopharmacol. 2012;143:57–67.
72. Zheng Y, et al. Effect of Maxing Shigan Tang on H1N1 influenza A virus-associated acute lung injury in mice. Intervirology. 2016;59:267–74.
73. Yang R, et al. Chemical composition and pharmacological mechanism of Qingfei-Paidu decoction and Ma Xing Shi Gan decoction against coronavirus disease 2019 (COVID-19): in silico and experimental study. Pharmaco Res. 2020;157:104820.
74. Zhang HL, Huang ZG, Jiang X, Qiu Y, Huang TM, Lin QZ, Liu TT. Study on the mechanism of Maxing Shigan decoction in the treatment of the severe novel coronavirus pneumonia based on network pharmacology. J Chin Med Mater. 2020;43:1777–83.
75. Zhang SY, Li L, Zhang N, Xia HT, Lu FG, Li WQ. Systematic pharmacological strategies to explore the regulatory mechanism of Ma Xing Shi Gan decoction on COVID-19. Dig Chin Med. 2020;3:96–115.
76. Na B. Study on the effect of Maxingxiang decoction combined with western medicine in the treatment of infantile pneumonia. Gud Chin Med. 2020;18:242.
77. Mou FZ, et al. Observation on curative effect of Maxing Shigan Sanren decoction in the treatment of new coronavirus pneumonia. J Trad Pract Chin Med. 2020;10:1259–60.
78. Cui W, et al. Total glycosides of Yupingfeng protects against bleomycin-induced pulmonary fibrosis in rats associated with reduced high mobility group box 1 activation and epithelial-mesenchymal transition. Inflamm Res. 2015;64:953–61.

79. Li L, et al. Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats. Phytomedicine. 2015;22:111–9.

80. Xu L, Li LC, Zhao P, Qi LW, Li P, Gao J, Fei GH. Total polysaccharide of Yupingfeng protects against bleomycin-induced pulmonary fibrosis via inhibiting transforming growth factor-β1-mediated type I collagen abnormal deposition in rats. J Pharm Pharmacol. 2014;66:1786–95.

81. Ma J, et al. Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chron Obstruct Pulm Dis. 2018;13:3107–14.

82. Wang R, Wang J, Shu J, Gu X, Li H, ZY, Liu S, Lin J. Efficacy and safety of Yu-Ping-Feng powder for asthma in children: a protocol of systematic review and meta-analysis of randomized controlled trials. Medicine. 2020;99: e18551.

83. Zhang JD, Lv J, Xie YM, Sun MH. Systematic evaluation and meta-analysis on effectiveness and safety of Yupingfeng granules on recurrent respiratory tract infection. Zhongguo Zhong Yao Za Zhi. 2019;44:4379–86.

84. Huang LL, Xu R, Liu YW, Liu ZY. Study on active compounds of Yupingfeng granules in preventing and treating COVID-19 based on network pharmacology and molecular docking. Pharmacol Clin Chin Mater Med. 2020;36:116–21.

85. Zhang D, Zhang B, Lv JT, Sa RN, Zhang XM, Lin ZJ. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence. Pharmacol Res. 2020;157: 104882.

86. National Health Commission of the People’s Republic of China. Diagnosis and treatment plan for COVID-19 (trial version 8 revision). Chin J Clin Infect Dis. 2021;14:81–8.

87. Agrahari R, Mohanty S, Vishwakarma K, Nayak SK, Samantaray D, Mohapatra S. Update vision on COVID-19: structure, immune pathogenesis, treatment and safety assessment. Sens Int. 2021;2: 100073.

88. Polidoro RB, Hagan RS, de Santis SR, Schmidt NW. Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19. Front Immunol. 2020;11:1626.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.